CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer

Alice Nomura; Sulagna Banerjee; Rohit Chugh; Vikas Dudeja; Masato Yamamoto; Selwyn M. Vickers; Ashok K. Saluja

doi:10.18632/oncotarget.3228

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer

Alice Nomura _, Sulagna Banerjee, Rohit Chugh, Vikas Dudeja, Masato Yamamoto, Selwyn M. Vickers and Ashok K. Saluja

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:8313-8322. https://doi.org/10.18632/oncotarget.3228

Metrics: PDF 2743 views | HTML 3117 views | ?

Abstract

Alice Nomura1, Sulagna Banerjee1, Rohit Chugh1, Vikas Dudeja1, Masato Yamamoto1, Selwyn M. Vickers1, Ashok K. Saluja1

1Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, USA

Correspondence to:

Ashok K. Saluja, e-mail: [email protected]

Keywords: CD133, pancreatic cancer, invasion, metastasis, NF-kB

Received: October 28, 2014 Accepted: January 27, 2015 Published: March 16, 2015

ABSTRACT

CD133 has been implicated as a cancer stem cell (CSC) surface marker in several malignancies including pancreatic cancer. However, the functional role of this surface glycoprotein in the cancer stem cell remains elusive. In this study, we determined that CD133 overexpression induced “stemness” properties in MIA-PaCa2 cells along with increased tumorigenicity, tumor progression, and metastasis in vivo. Additionally, CD133 expression induced epithelial-mesenchymal transition (EMT) and increased in vitro invasion. EMT induction and increased invasiveness were mediated by NF-κB activation, as inhibition of NF-κB mitigated these effects. This study showed that CD133 expression contributes to pancreatic cancer “stemness,” tumorigenicity, EMT induction, invasion, and metastasis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3228

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer

Abstract